Charles E. Geyer, MD, FACP, discusses dosing strategies and adverse event management with olaparib.
Charles E. Geyer, MD, FACP
Advertisement
Articles by Charles E. Geyer, MD, FACP
Advertisement
Latest Updated Articles
Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast CancerPublished: March 28th 2022 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC
2
Pembrolizumab Plus RT Ups T-Cell Infiltration in Early Breast Cancer
3
Progression Occurs Early in R/R LBCL Treated With Epcoritamab, Glofitamab
4
Teclistamab/Daratumumab Increases OS, PFS in R/R Multiple Myeloma
5
